BioSpace News Archive

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies Healthcare Conference.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated pancreatic islet cell replacement therapy, have been accepted for presentation during the American Diabetes Association 82nd Annual Scientific Sessions Conference held June 3-7, 2022.

Secarna is pleased to announce that the Company’s partner Lipigon Pharmaceuticals AB (“Lipigon”) has advanced their lead candidate, Lipisense , into a phase 1 clinical study.

Agenus Inc. announced that it has entered into 3 new clinical collaborations with Targovax, Oxford BioTherapeutics, and Immunogenesis, doubling its current number of clinical collaborations.

Virax Biolabs Group Limited, an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, is pleased to announce the appointment of an unparalleled group of thought leaders to a newly formed advisory board to provide guidance and support to the Virax senior leadership team.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that its subsidiary company, UR-1 Therapeutics, Inc. (“UR-1”), dosed the first patient in a Phase 1 clinical trial evaluating Dotinurad for the treatment of gout in the United States.

ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.

Blue Water Vaccines Inc. a biopharmaceutical company developing transformational vaccines to address significant global health challenges, announced the signing of an amendment to its existing Sponsored Research Agreement with The University of Oxford.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.